Northbound funds have swept away again, and the A-share rising wave is coming? The medical sector went crazy, and the 290 billion “eye mao” once soared by 15%

Northbound funds have swept away again, and the A-share rising wave is coming? The medical sector went crazy, and the 290 billion “eye mao” once soared by 15%

In early trading today, A-shares fluctuated slightly. The ChiNext index rose by more than 2%, and hit a new high since the rebound. On the disk, sectors such as health care, beer, electrical equipment, and polysilicon were active, with aquatic products, medical beauty concepts, and digital currencies leading the decline in early-stage popular sectors. The net inflow of funds to the north was over 5.5 billion yuan.

Health care frequent performance surge

Benefiting from the surge in demand from the epidemic, the healthcare industry has ushered in a peak period of performance. After the 2021 quarterly report of Hotview Biotechnology increased by more than a thousand times, last night, a number of blockbuster listed companies in the health care sector announced their excellent quarterly reports at the same time.

Ingram Medical released its report for the first quarter of 2021 last night, achieving operating income of 6.735 billion yuan, a year-on-year increase of 770.86%, net profit of 3.736 billion yuan, a year-on-year increase of 2791.66%, and net cash flow from operating activities of 3.075 billion yuan, a year-on-year increase An increase of 1013.67%. Ingram Medical said that benefiting from the strong demand for disposable gloves at home and abroad, and the company’s new annual production capacity of 9 billion nitrile gloves in the company’s Anhui production base, the company’s profit in the first quarter increased by 41.80% from the previous quarter, and its single-quarter performance reached a new high.

Although Ingram Medical has risen by more than 30 times in recent years, the surging performance growth has made Ingram Medical’s dynamic price-earnings ratio still only over 4 times, even lower than most bank stock-earnings ratios. Stimulated by the surge in the quarterly report, Intech Medical opened higher in the morning and rose by more than 10% during the session. Or they may have some expectations for the performance of Ingram Medical’s first quarterly report. Financing customers reversed the previous five consecutive weeks of net sales this Monday and bought 30.5 million yuan.

Aier Ophthalmology also announced that it achieved operating income of 3.511 billion yuan in the first quarter, an increase of 113.9% year-on-year, and a net profit of 484 million yuan, an increase of 509.88% year-on-year. Aier Ophthalmology also opened high volume in early trading, rose by more than 15% at one time, and the half-day turnover exceeded the full-day turnover of the previous trading day by more than double. Similarly, financing customers this week raised a net purchase of 222 million yuan in advance, waiting for the good performance to be realized.

Driven by the surge in Ingram Medical and Aier Ophthalmology, the entire health care sector surged. The sector index once soared by more than 4% during the intraday session, setting a new high in 2 months. This is the index’s sixth consecutive trading day. rise. Hotview Biotech once again reached a 20% daily limit in the intraday trading, and its stock price also hit a record high. Since the announcement of the first quarterly report, it has risen by more than 200% in just 9 trading days; Yihua Health, Gongdong Medical, Dabo Medical and other daily limit.

The surge in the healthcare sector also led to a surge in medical ETFs. In early trading, Fortune CSI Medical Open-end Index Securities Investment Fund rose 3.64%; Cathay Pacific CSI Medical Open-end Index Securities Investment Fund rose 3.53%; Tianhong Zhong The Securities Index Securities Investment Fund rose 3.28% and hit a record high.

The consumption peak season is coming, the beer sector is active

The beer sector also released a quarterly report last night. The first quarterly report of Lanzhou Yellow River showed that it turned losses into profits, with a net profit of 8.3165 million yuan. Lanzhou Huanghe stated that in the first quarter of 2020, due to the impact of the new crown pneumonia epidemic, the company’s operating income fell sharply and its performance suffered a loss. Since 2021, as the domestic epidemic prevention and control situation continues to improve, the company’s beer and malt production and sales in the first quarter have increased significantly compared with the same period last year, and securities investment disposal and holding income that are non-recurring gains and losses have also increased significantly compared with the same period last year. , The two superimposed, the company’s performance realized a turnaround. After the Lanzhou Yellow River opened slightly higher in the morning, it only took about 5 minutes to pull the daily limit straight.

Although Huiquan Beer reported a quarterly loss of 3,968,500 yuan, it was significantly narrower than the loss of 7,077,600 yuan in the same period last year, and its operating income was 121 million yuan, a year-on-year increase of 10.54%. In the morning, Huiquan Beer opened low and moved high and soared by nearly 7%.

Zhujiang Beer is scheduled to disclose the 2021 quarterly report this evening. Driven by the surge of Lanzhou Yellow River and Huiquan beer, and the advent of the superimposed peak summer consumption season, Zhujiang Beer once hit the daily limit in early trading, and its share price hit a new high during the year. Zhujiang Beer’s 2020 annual report showed that it achieved a net profit of 569 million yuan, a year-on-year increase of 14.43%; Chongqing Beer and other companies also strengthened in the market.

Minsheng Securities pointed out that looking forward to the whole year of 2021, it is expected that the production and sales of the beer industry will achieve recovery growth under the low base last year. The industry TOP5 has formed a firm consensus on high-end and profit demands, and the overall competition in the industry has slowed down and the certainty is high. Recommended ranking: Yanjing Beer + Tsingtao Beer + Chongqing Beer + Zhujiang Beer combination, and pay attention to H shares of China Resources Beer, Budweiser Asia Pacific.

Favorites

Report